| Cousin, Sophie |
| Active, not recruiting | 3 | 327 | Europe, RoW | Radiotherapy, 3D-CRT or SABR, Pembrolizumab, Chemotherapy, Carboplatin, paclitaxel, nab-paclitaxel, cisplatin, pemetrexed | UNICANCER, National Cancer Institute, France | Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Metastatic, Non-Small Cell Carcinoma of Lung, TNM Stage 4 | 01/26 | 07/27 | | |
ADOPT-lung, NCT06284317: A Study to Evaluate the Benefit of Adding Durvalumab After Chemotherapy, Durvalumab and Surgery in Patients with Early-stage, Operable, Non-small Cell Lung Cancer. |
|
|
| Recruiting | 3 | 290 | Europe, RoW | Adjuvant durvalumab | ETOP IBCSG Partners Foundation, AstraZeneca AG Switzerland | Non Small Cell Lung Cancer | 10/29 | 03/30 | | |
| Completed | 3 | 136 | Europe | Imatinib maintenance, Glivec, Imatinib mésilate | Centre Leon Berard, INCA | Gastrointestinal Stromal Tumors, Resected Gastrointestinal Stromal Tumors, Non-metastatic, High Risk of Recurrence, KIT Gene Mutation | 12/23 | 12/23 | | |
NCT06095583: Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC) |
|
|
| Recruiting | 3 | 756 | Europe, US, RoW | Tifcemalimab injection, toripalimab injection, Placebo for Tifcemalimab, Placebo for toripalimab | Shanghai Junshi Bioscience Co., Ltd. | Limited-stage Small Cell Lung Cancer (LS-SCLC) | 07/27 | 07/29 | | |
| Terminated | 2 | 3 | Europe, US, RoW | KRT-232, navtemadlin | Kartos Therapeutics, Inc. | Small-cell Lung Cancer, Small Cell Lung Carcinoma, Small Cell Lung Cancer Extensive Stage, Small Cell Lung Cancer Recurrent | 08/22 | 08/22 | | |
PECATI, NCT04710628: Combination of Pembrolizumab and Lenvatinib, in Pre-treated Thymic CArcinoma paTIents |
|
|
| Active, not recruiting | 2 | 43 | Europe | Pembrolizumab, MK-3475, lambrolizumab, Lenvatinib 10 mg, E7080 | MedSIR, Merck Sharp & Dohme LLC | Metastatic Thymic Carcinoma, Thymoma Type B3 | 07/24 | 01/26 | | |
LENVAGIST, NCT04193553: Multicentre Placebo-controlled Double-blinded Phase II Study of Lenvatinib Efficacy in Patients With Locally Advanced or Metastatic GIST (Gastrointestinal Stromal Tumor) After Imatinib/Sunitinib Failure |
|
|
| Completed | 2 | 77 | Europe | Lenvatinib, Placebo, Best supportive care | Centre Leon Berard | Gastro Intestinal Stromal Tumour | 01/24 | 04/24 | | |
| Recruiting | 2 | 119 | Europe | Encorafenib 75 MG, Binimetinib 15 MG | Intergroupe Francophone de Cancerologie Thoracique, IFCT, Pierre Fabre | Non Small Cell Lung Cancer, BRAF V600E | 12/24 | 03/26 | | |
|
| Completed | 2 | 127 | Europe | Regorafenib, stivarga, Placebo | Centre Oscar Lambret | Metastatic Soft Tissue Sarcoma | 03/24 | 09/24 | | |
| Withdrawn | 2 | 82 | Europe | Association of lurbinectedin and durvalumab, Association of carboplatin and etoposide | Institut Bergonié, AstraZeneca, PharmaMar | Small Cell Lung Cancer, Platinum-Sensitive Lung Small Cell Carcinoma, Extensive-stage Small-cell Lung Cancer | 05/24 | 05/24 | | |
MOST plus, NCT02029001: Adapting Treatment to the Tumor Molecular Alterations for Patients With Advanced Solid Tumors: MyOwnSpecificTreatment |
|
|
| Recruiting | 2 | 900 | Europe | Nilotinib (400 mg BID), Open cohort, Everolimus (10 mg QD), Closed cohort, Sorafenib (400 mg BID), Lapatinib (1500 mg QD), Pazopanib (800 mg QD), Olaparib (300 mg BID), Durvalumab + Tremelimumab | Centre Leon Berard, National Cancer Institute, France | Malignant Solid Neoplasms | 01/26 | 10/27 | | |
GIST-TEN, NCT05009927: Efficiency of Imatinib Treatment After 10 Years of Treatment in Patients With Gastrointestinal Stromal Tumours (GIST) (Gist-Ten) |
|
|
| Recruiting | 2 | 50 | Europe | Imatinib tablets, Glivec | Centre Leon Berard | Metastatic Gastrointestinal Stromal Tumor (GIST), C-KIT Mutation, Advanced Gastrointestinal Stromal Tumor (GIST) | 01/25 | 01/27 | | |
| Not yet recruiting | 2 | 115 | Europe | Atezolizumab 1200 mg IV, Tiragolumab 600 mg IV | Gustave Roussy, Cancer Campus, Grand Paris, Roche Global Development | Metastatic Cancer Lung, Advanced Lung Cancer, CBNPC Cancer | 01/28 | 01/30 | | |
| Recruiting | 2 | 340 | Europe, Japan, US, RoW | Pembrolizumab, Dostarlimab, GSK4057190, Belrestotug, EOS884448, GSK4428859A, Nelistotug, GSK6097608 | GlaxoSmithKline, iTeos Therapeutics | Lung Cancer, Non-Small Cell | 10/25 | 10/28 | | |
NCT04621188: Lorlatinib After Failure of First-line TKI in Patients with Advanced ROS1-positive NSCLC (ALBATROS) |
|
|
| Recruiting | 2 | 84 | Europe | Lorlatinib | Intergroupe Francophone de Cancerologie Thoracique | Non Small Cell Lung Cancer Metastatic | 03/25 | 01/26 | | |
A2A-005, NCT05403385: Study of Inupadenant (EOS100850) with Chemotherapy As Second Line Treatment for Nonsquamous Non-small Cell Lung Cancer |
|
|
| Recruiting | 2 | 186 | Europe, Canada, US, RoW | inupadenant, EOS100850, Placebo, Carboplatin, Pemetrexed, Alimta | iTeos Therapeutics, iTeos Belgium SA | Metastatic NSCLC - Non-Small Cell Lung Cancer, Locally Advanced NSCLC - Non-Small Cell Lung Cancer | 04/25 | 05/25 | | |
NCT03739710 / 2018-001316-29: Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) |
|
|
| Completed | 2 | 176 | Europe, Canada, US, RoW | Docetaxel, Feladilimab, Ipilimumab, GSK4428859A, belrestotug, EOS884448, Dostarlimab, GSK6097608 | GlaxoSmithKline, iTeos Belgium SA | Neoplasms | 05/24 | 05/24 | | |
| Active, not recruiting | 2 | 80 | Europe | ICI treatment discontinuation, ICI treatment continuation | Institut Bergonié | Non Small Cell Lung Cancer | 08/25 | 08/26 | | |
MegaMOST, NCT04116541: A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/characteristics in Advanced / Metastatic Tumors. |
|
|
| Recruiting | 2 | 455 | Europe | HDM201, Closed cohort, Ribociclib, Cabozantinib, Open cohort, Alectinib, Regorafenib, Trametinib, Dabrafenib, Avapritinib | Centre Leon Berard | Malignant Solid Tumor | 02/26 | 11/26 | | |
| Recruiting | 2 | 60 | Europe | Amivantamab, Lazertinib, Zirabev | ETOP IBCSG Partners Foundation, Janssen Pharmaceuticals | Non Small Cell Lung Cancer | 03/26 | 09/26 | | |
EXPAND-1, NCT06470763: A Study Evaluating ANV600 Single Agent or in Combination with Pembrolizumab in Participants with Advanced Solid Tumors |
|
|
| Recruiting | 1/2 | 240 | Europe, US | ANV600, ANV600 + pembrolizumab (KEYTRUDA®) | Anaveon AG, Merck Sharp & Dohme LLC | Advanced Solid Tumor | 10/27 | 02/28 | | |
| Recruiting | 1/2 | 747 | Europe | Phase 1 : Regorafenib, Phase 1 : Avelumab, Phase 2 : Regorafenib, Phase 2 : Avelumab, Phase 2: low-dose Regorafenib | Institut Bergonié, Bayer, Merck KGaA, Darmstadt, Germany | Colorectal Cancer Not MSI-H or MMR-deficient, GIST, Oesophageal or Gastric Carcinoma, Biliary Tract Cancer, Hepatocellular Carcinoma, Soft-tissue Sarcoma, Thyroid Cancer, Gastro-enteropancreatic Neuroendocrine Tumor, Non-small Cell Lung Cancer, Solid Tumor, Adult, Urothelial Carcinoma, HPV-Related Carcinoma, Triple Negative Breast Cancer, Renal Carcinoma, Mesotheliomas Pleural | 12/24 | 12/25 | | |
CFT1946-1101, NCT05668585: A Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and Combination Therapy in Subjects With BRAF V600 Mutant Solid Tumors |
|
|
| Recruiting | 1/2 | 206 | Europe, US | CFT1946, Trametinib, Cetuximab | C4 Therapeutics, Inc. | Solid Tumors, Melanoma, NSCLC, CRC, ATC | 03/27 | 04/27 | | |
| Recruiting | 1 | 198 | Europe, US, RoW | ELVN-002, Fam-Trastuzumab Deruxtecan-Nxki, Enhertu, T-DXd, Trastuzumab emtansine, Kadcyla, T-DM1 | Enliven Therapeutics | HER2 Mutant Non-small Cell Lung Cancer, HER2-positive Metastatic Breast Cancer, HER2 Gene Mutation, HER2 Amplification | 07/26 | 07/26 | | |
| Completed | N/A | 179 | Europe, Canada, RoW | | Takeda | Non-small Cell Lung Cancer (NSCLC) | 02/23 | 02/23 | | |
CIRCULAR, NCT04912687: Implementing Circulating Tumor DNA Analysis at Initial Diagnosis to Improve Management of Advanced NSCLC Patients |
|
|
| Recruiting | N/A | 580 | Europe | EGFR gene mutation analysis on liquid biopsy | Institut Bergonié, AstraZeneca | Non Small Cell Lung Cancer, Advanced Solid Tumor | 01/25 | 01/26 | | |
| Active, not recruiting | N/A | 25 | Europe | Patient treated by Avapritinib in real life | Centre Leon Berard, Blueprint Medicines Corporation | GIST, GIST, Malignant, PDGFR-Alpha D842V | 04/24 | 12/24 | | |
| Sophie, Cousin |
| No trials found |
